Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair.
The post Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science appeared first on MedCity News.
